Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Marko Kralik

32105

Marko

Kralik

dr. sc.

nije evidentirano
Naziv Akcije
Dobrenić, Margareta ; Kralik, Marko ; Divošević, Sunčana Hrvatski konsenzus o dijagnostici i liječenju limfoma - zaključci Radne skupine za slikovnu dijagnostiku // Bilten Krohema, 15 (2023), 1; 3-7
Premužić, Vedran ; Bašić-Kinda, Sandra ; Radman, Ivo ; Dujmović, Dino ; Ilić, Ivana ; Živković, Neno ; Maleta, Lucija ; Kralik, Marko ; Dobrenić, Margareta ; Galunić-Bilić, Lea et al. Glomerular filtration rate is an independent prognostic factor in patients with B-large cell lymphoma // Medicine, 102 (2023), 20; 33675, 5. doi: 10.1097/MD.0000000000033675
Hude Dragičević, Ida ; Bašić-Kinda, Sandra ; Dujmović, Dino ; Radman, Ivo ; Dreta, Barbara ; Dotlić, Sandra ; Galunić- Bilić, Lea ; Dobrenić, Margareta ; Kralik, Marko ; Rončević, Pavle et al. Reduced steroid exposure is safe and does not reduce disease control among Hodgkin lymphoma patients treated with escalated BEACOPP (eBEACOPP) // The 12th International Symposium on Hodgkin Lymphoma Abstract Book, HemaSPhere 6(S5). 2022. str. 8-9
Bašić-Kinda, Sandra ; Radman, Ivo ; Dujmović, Dino ; Ilić, Ivana ; Kralik, Marko ; Dobrenić, Margareta ; Galunić-Bilić, Lea ; Rončević, Pavle ; Vodanović, Marijo ; Sertić, Zrinka et al. R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience // Annals of hematology, 100 (2021), 6; 1517-1524. doi: 10.1007/s00277-020-04353-3
Basic-Kinda, Sandra ; Dujmovic, Dino ; Radman, Ivo ; Moric Peric, Martina ; Hude, Ida ; Durakovic, Nadira ; Vodanovic, Marijo ; Dobrenic, Margareta ; Kralik, Marko ; Galunic-Bilic, Lea et al. eBEACOPP for front-line treatment of patients with classical Hodgkin lymphoma (cHL) in the real world setting. 2018. str. 26-26
Božina, Nada ; Bilić, Ivan ; Pleština, Stjepko ; Vrbanec, Damir ; Kralik, Marko ; Ganoci, Lana DPYD polymorphisms and fluoropyrimidine toxicity- a single institution case control study // Abstract Book of the 15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology / - : IATDMCT, 2017. 2017
Hrabak Paar, Maja ; Kralik, Marko Case 244 // Radiology, 283 (2017), 1; 300-302. doi: 10.1148/radiol.2017151157
Hrabak-Paar, Maja ; Kralik, Marko Case 244 : Systemic Amyloidosis—A Complication of Waldenström Macroglobulinemia // Radiology, 284 (2017), 2; 597-602. doi: 10.1148/radiol.2017151156
Aurer, Igor ; Nemet, Damir ; Mitrović, Zdravko ; Dujmović, Dino ; Bašić-Kinda, Sandra ; Radman, Ivo ; Sertić, Dubravka ; Šantek, Fedor ; Kralik, Marko ; Dotlić, Snježana et al. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma // Annals of hematology, 95 (2016), 7; 1129-1136. doi: 10.1007/s00277-016-2676-0
Aurer, Igor ; Basic-Kinda, Sandra ; Dujmovic, Dino ; Radman, Ivo ; Dreta, Barbara ; Dotlic, Snjezana ; Galunic-Bilic, Lea ; Dobrenic, Margareta ; Kralik, Marko ; Roncevic, Pavle The switch from ABVD to eBEACOPP as front-line therapy for high-risk patients stage III-IV Hodgkin lymphoma (CHL) patients results in an inversion of event-free survival (EFS) of prognostic groups. 2016. str. 24-24
nije evidentirano
nije evidentirano